- In October 2021, BioLife Plasma Services (U.S.) launched a new plasma center in Worcester, to address the rising demand for plasma-based therapies
- In August 2021, Biotest AG (Germany) opened its sixth plasma collection center in the Czech Republic, ensuring a long-term supply of plasma for therapeutic needs
- In July 2020, Grifols, a prominent producer of plasma-derived medicines, signed an agreement with GC Pharma to acquire a plasma fractionation facility in Montreal, along with 11 U.S.-based plasma collection centers and two purification facilities, strengthening its market position and revenue
- In June 2020, CSL Behring (Australia) reached an agreement to acquire Vitaeris Inc., a clinical-stage biotechnology company, to advance the Phase III development of canakinumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB)
- In March 2020, Takeda Pharmaceutical Company Limited initiated the development of anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)-TAK-888 for COVID-19 treatment, accelerating therapeutic advancements for effective disease management
